Developing life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and patients to pharma and industry.
Switzerland's AC Immune biopharma has begun mid-stage trials of a vaccine against Alzheimer’s disease and Abeta-related cognitive decline in Down Syndrome patients.
